The aim of the research: to experimentally study at the histological and morphological level the degree of the corrective effect of bacterial lysate of the disturbed non-specific defense of the body on the model of periodontitis based on the Central Research Laboratory of the National University of Pharmacy.
Materials and methods: prospective study has been conducted on experimental periodontitis in 42 rats for 90 days. The animals were treated with «Respibron» and the reference drug «Imudon». Histological and morphometric studies were carried out according to standard methods. Micropreparations were viewed under a Granum DCM 310 digital video camera. All interventions and euthanasia of animals were carried out in compliance with the European principles.
Results: by the end of 90 days of experimental periodontitis at the local level in the homogenate of animal gum tissue compensatory mechanisms are depleted and differed from the norm by 397 times. The dynamics of the studied morphometric and histological parameters of "Respibron" was similar to the "Imudon", but the magnitude of destruction was less pronounced and differed at the end of the experiment by 17.2 times in comparison with the intact control, and in the control group the results improved by 23.1 times.
Conclusion: the obtained data from the study indicate a high decompensation of experimental periodontitis. It is characterized by the formation of periodontal pockets and inflammatory bone loss. The magnitude of destruction differed from the norm by 397 times. Applying of bacterial lysates led to the compensation of bacterial dysbiosis, restoration of the tissues of paradont. The therapeutic effect of "Respibron" can be assessed as more powerful in comparison with "Imudon" in terms of the studied morphometric and histological parameters: the magnitude of improvement "Respibron" was 3.72 times higher than the indicators of "Imudon". We should continue the study of experimental periodontitis as mechanisms of development, protection, and restoration of tissues under conditions of pharmacological correction by bacterial lysate "Respibron"